2024-06-05 08:50:35 ET
More on Harmony Biosciences
- Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade)
- Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline
- Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M
- Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
- Harmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call Presentation
Read the full article on Seeking Alpha
For further details see:
Harmony releases promising phase 2 results of pitolisant for myotonic dystrophy